title: Adoptive cellular therapy for cytomegalovirus infection following allogeneic stem cell transplantation using virus-specific T cells.
abstract: Adoptive transfer of virus-specific T cells offers the potential for accelerating reconstitution of antigen-specific immunity and limiting the morbidity and mortality of viral infections following allogeneic haematopoietic stem cell transplantation. However, the logistics of producing virus-specific T cells and the risk of inducing graft-versus-host disease secondary to the infusion of alloreactive clones have limited the application of cellular therapies. We report the results in patients of pre-emptive and prophylactic therapy with cytomegalovirus-specific T cells. Cells were administered at early time points following transplantation (when the risk of GVHD is greatest) either prophylactically or following the detection of CMV DNA by a PCR-based surveillance technique. Massive in vivo expansions of CMV-specific cytotoxic T-lymphocytes (3-5 log) were observed in patients within days of adoptive transfer. Viral titers were decreasing within 5 days, in some patients the T-cell receptor CDR3 lengths of CMV-specific CTL expanding in vivo were identical to those of the transferred cells. A low incidence of late cytomegalovirus reactivation was seen and no significant toxicities were observed. Our findings indicate that application of cell lines generated by either short-term in vitro cultures or by direct selection using gamma-capture, which allow expansion of both CD4(+) and CD8(+) virus-specific T cells, is both feasible and effective in a clinical environment. These simple in vitro methodologies should allow widespread application of adoptive transfer of virus-specific T cells.
authors.affiliation: Department of Haematology, Royal Free and University College London Medical School, Pond Street, London NW3 2QG, UK. s.mackinnon@ucl.ac.uk
authors.forename: Stephen
authors.initials: S
authors.lastname: Mackinnon
authors.forename: Kirsty
authors.initials: K
authors.lastname: Thomson
authors.forename: Stephanie
authors.initials: S
authors.lastname: Verfuerth
authors.forename: Karl
authors.initials: K
authors.lastname: Peggs
authors.forename: Mark
authors.initials: M
authors.lastname: Lowdell
mesh_terms: D019264:Adoptive Transfer; D000956:Antigens, Viral / Q000276:immunology*; D018929:Cell Culture Techniques; D049109:Cell Proliferation; D002469:Cell Separation; D003586:Cytomegalovirus Infections / Q000209:etiology / Q000628:therapy*; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006801:Humans; D013601:T-Lymphocytes / Q000276:immunology*; D013997:Time Factors; D014184:Transplantation, Homologous; D019562:Viral Load
chemical_list: D000956:Antigens, Viral